This article was originally published in The Gray Sheet
Company's SRS cement is more appropriately classified as an "internal fixation device" rather than a "bone void filler," as was reported in the Jan. 4 issue of "The Gray Sheet" (p. 15), since it is resorbed in vivo, rather than dissolved, and it offers compressive strength, the company states. Norian's trial treated 75 intra-articular fractures, and only four patients reported adverse events, leading FDA to decide that long-term follow-up on those cases would be inconclusive. Norian also clarifies that the difference in average radial length loss between SRS and control patients was not statistically significant
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.